JACOB (NCT01774786) was a prospective, randomized, multicenter, multinational, double-blind, placebo-controlled, phase III trial that evaluated the efficacy and safety of the new pertuzumab dosing regimen of 840 mg q3w administered intravenously (IV) plus trastuzumab and chemotherapy (pertuzumab arm), compared with placebo plus trastuzumab and chemotherapy (placebo arm) as first-line therapy in patients with previously untreated HER2-positive metastatic GC or gastroesophageal junction cancer (MGC/GEJC) [11]. The gene discussed is ERBB2; the disease is gastric cancer.